Article
A pilot and open trial to evaluate topical Bacterial Cellulose bio-curatives in the treatment of cutaneous leishmaniasis caused by L. braziliensis
Registro en:
CELES, Fabiana S. et al. A pilot and open trial to evaluate topical Bacterial Cellulose bio-curatives in the treatment of cutaneous leishmaniasis caused by L. braziliensis. Acta Tropica, v. 225, 2022.
0001-706X
10.1016/j.actatropica.2021.106192
Autor
Celes, Fabiana S.
Barud, Hernane S.
Viana, Sayonara M.
Borba, Pedro B.
Machado, Paulo R. L.
Carvalho, Edgar Marcelino
Oliveira, Camila Indiani de
Resumen
Conselho Nacional de
Desenvolvimento Científico e Tecnol´ogico (CNPq) (440107/2018-0) H.
B.; P.M., E.M.C., L.C. and C.I.O are senior researchers CNPq. F.S.C, P.B.B
and S.M.V received a fellowship from Coordenaç˜ao de Aperfeiçoamento
de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. H. S.
Barud was supported by CNPq (Grant No. 407822/2018-6; INCT-INFO),
S˜ao Paulo Research Foundation (FAPESP) (Grants no. 2018/25512-8
and no. 2013/07793-6), and TA Instruments Brazil. The treatment of cutaneous leishmaniasis (CL) in Brazil using pentavalent antimony (Sbv) is associated with a
high failure rate and long time to heal. Moreover, standard Sbv treatment cures only 50–60% of the cases. In this
pilot clinical trial, we evaluated the topical use of bacterial cellulose (BC) bio-curatives + Sbv in the treatment of
CL caused by L. braziliensis, in Bahia, Brazil. A total of 20 patients were randomized in two groups assigned to
receive either parenteral Sbv alone or parenteral Sbv plus topically applied BC bio-curatives. CL patients treated
with Sbv + topical BC bio-curatives had a significantly higher cure rate at 60 days post initiation of treatment
compared to CL patients treated with Sbv alone (P=0.01). At day 90 post initiation of treatment, cure rate was
similar in the two groups as was overall healing time. Adverse effects or local reactions to topical BC application
were not observed. This pilot trial shows that the potential use of a combined therapy consisting of topical BC
bio-curatives and parenteral Sbv in favoring healing of CL lesions caused by L. braziliensis, at an early time point.